Yahoo Finance

HOOKIPA Announces FDA Clearance of its IND Application for HB-202/201 Clinical Trial to Treat HPV-Positive Cancers

NEW YORK and VIENNA, Austria, June 17, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (HOOK), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on ...
Yahoo Finance

HOOKIPA Interim Phase 1 Monotherapy Data of HB-201 for the Treatment of Advanced HPV16+ Cancers Shows Promising Anti-Tumor Activity and Favorable Tolerability

Data demonstrate responses and stable disease in some head and neck cancer patients who all received at least two prior therapies and progressed on a PD1 inhibitor By targeting an antigen common to ...
Nasdaq

HOOKIPA to Present Complete HB-200 Phase 1 Results and Recommended Phase 2 Dose for HB-202/HB-201 for the Treatment of Advanced HPV16+ Cancers at ASCO

Phase 1 data show single-vector HB-201 and 2-vector HB-202/HB-201 were generally well tolerated, rapidly induced tumor-specific T cells and showed anti-tumor activity in heavily pre-treated head and ...
Business Insider

HOOKIPA Announces First Patient Dosed in Phase 1/2 Clinical Trial for HB-202/HB-201 Alternating Vector Therapy to Treat Human Papillomavirus 16-Positive Cancers

- HB-202/HB-201 alternating two-vector therapy is added as an additional arm that expands the ongoing HB-201 clinical trial - Pre-clinical data show that adding an additional arenaviral vector to ...